At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
TAK-385drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of TAK-385 Alone in Hormone Treatment- naïve Japanese Patients With Non-metastatic Prostate Cancer
In Brief
A Phase 1 clinical trial evaluating TAK-385 for Hormone Treatment-naïve Participants With Prostate Cancer. Completed, enrolled 43 participants across 6 sites.
Detailed Summary
The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionApr 2017
TodayJul 2026
First PostedMay 19, 2014
Enrollment StartMay 1, 2014
Primary CompletionApr 20, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.1 years ago
Interventions
TAK-385drug
TAK-385 Tablets.